See more : ISDN Holdings Limited (1656.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Eisai Co., Ltd. (ESALF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eisai Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Qomolangma Acquisition Corp. (QOMO) Income Statement Analysis – Financial Results
- Murphy Canyon Acquisition Corp. (MURFU) Income Statement Analysis – Financial Results
- Asseco Business Solutions S.A. (ABS.WA) Income Statement Analysis – Financial Results
- Gold cup Electric Apparatus Co.,Ltd. (002533.SZ) Income Statement Analysis – Financial Results
- Euro Ceramics Limited (EUROCERA.NS) Income Statement Analysis – Financial Results
Eisai Co., Ltd. (ESALF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eisai.co.jp
About Eisai Co., Ltd.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 741.75B | 744.40B | 756.23B | 645.94B | 695.62B | 642.83B | 600.05B | 539.10B | 547.92B | 548.47B | 599.49B | 573.68B | 647.93B | 768.93B | 803.14B | 781.71B | 734.42B | 674.18B | 601.26B | 533.14B | 500.13B | 466.48B | 431.67B | 361.84B | 302.47B |
| Cost of Revenue | 155.33B | 200.93B | 186.44B | 180.76B | 185.27B | 196.40B | 213.46B | 208.01B | 208.08B | 193.60B | 194.66B | 174.11B | 173.35B | 167.78B | 160.73B | 152.41B | 118.94B | 109.37B | 104.51B | 98.61B | 97.18B | 102.47B | 101.57B | 98.60B | 91.68B |
| Gross Profit | 586.42B | 543.48B | 569.79B | 465.19B | 510.35B | 446.44B | 386.60B | 331.09B | 339.84B | 354.87B | 404.83B | 399.57B | 474.57B | 601.15B | 642.41B | 629.29B | 615.48B | 564.81B | 496.75B | 434.53B | 402.95B | 364.01B | 330.10B | 263.24B | 210.79B |
| Gross Profit Ratio | 79.06% | 73.01% | 75.35% | 72.02% | 73.37% | 69.45% | 64.43% | 61.42% | 62.02% | 64.70% | 67.53% | 69.65% | 73.24% | 78.18% | 79.99% | 80.50% | 83.81% | 83.78% | 82.62% | 81.50% | 80.57% | 78.03% | 76.47% | 72.75% | 69.69% |
| Research & Development | 169.02B | 156.69B | 158.03B | 138.82B | 125.49B | 127.63B | 131.09B | 104.27B | 110.86B | 131.91B | 136.31B | 120.38B | 0.00 | 0.00 | 0.00 | 0.00 | 225.43B | 108.30B | 93.25B | 78.33B | 69.02B | 59.70B | 55.04B | 49.61B | 46.70B |
| General & Administrative | 374.42B | 358.29B | 366.43B | 281.63B | 256.30B | 228.21B | 183.86B | 174.94B | 192.82B | 194.55B | 203.34B | 139.85B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Selling & Marketing | 0.00 | -10.73B | -14.29B | -11.81B | -10.11B | -9.32B | -3.94B | 671.00M | -6.95B | 0.00 | 58.22B | 68.88B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 374.42B | 347.56B | 352.14B | 269.82B | 246.18B | 218.89B | 179.92B | 175.61B | 185.87B | 194.55B | 203.34B | 208.73B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Other Expenses | -10.43B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -338.00M | 0.00 | -109.00M | -138.00M | 69.00M | 924.00M | 417.00M | -9.00M | 670.00M | 712.00M | 565.00M | 580.00M | -63.00M | 467.00M | 864.00M | 1.77B | 0.00 |
| Operating Expenses | 533.01B | 504.26B | 510.17B | 408.64B | 371.67B | 346.52B | 311.00B | 279.89B | 297.06B | 326.53B | 338.43B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 597.73B | 459.55B | 401.04B | 347.72B | 319.88B | 288.15B | 257.50B | 204.27B | 173.66B |
| Cost & Expenses | 688.34B | 705.18B | 696.60B | 589.40B | 556.94B | 542.91B | 524.46B | 487.89B | 505.14B | 520.13B | 533.09B | 503.21B | 552.17B | 655.81B | 716.73B | 689.90B | 716.67B | 568.91B | 505.55B | 446.33B | 417.06B | 390.61B | 359.06B | 302.88B | 265.34B |
| Interest Income | 10.80B | 4.62B | 1.68B | 1.30B | 3.26B | 4.16B | 1.75B | 1.08B | 1.20B | 2.43B | 1.79B | 1.12B | 815.00M | 997.00M | 1.25B | 3.17B | 5.33B | 5.12B | 3.35B | 1.70B | 1.34B | 1.47B | 2.44B | 3.19B | 0.00 |
| Interest Expense | 2.39B | 2.27B | 1.69B | 1.19B | 1.17B | 1.46B | 2.83B | 2.78B | 3.46B | 4.89B | 5.89B | 6.69B | 6.89B | 7.42B | 7.66B | 7.63B | 762.00M | 65.00M | 79.00M | 52.00M | 28.00M | 56.00M | 296.00M | 687.00M | 1.13B |
| Depreciation & Amortization | 39.40B | 39.98B | 38.40B | 36.30B | 33.70B | 26.84B | 26.18B | 26.48B | 34.06B | 38.94B | 39.93B | 51.09B | 48.69B | 51.26B | 57.37B | 58.63B | 34.40B | 26.80B | 24.99B | 22.36B | 18.49B | 17.97B | 17.97B | 15.00B | 15.14B |
| EBITDA | 103.61B | 79.20B | 94.55B | 89.42B | 163.23B | 117.85B | 101.78B | 77.69B | 76.84B | 69.71B | 108.12B | 129.21B | 150.23B | 161.25B | 144.72B | 136.75B | 52.81B | 137.20B | 121.15B | 110.06B | 101.88B | 94.16B | 81.02B | 78.93B | 41.81B |
| EBITDA Ratio | 13.97% | 10.64% | 12.96% | 14.37% | 24.78% | 19.72% | 16.96% | 14.41% | 14.02% | 12.71% | 18.03% | 21.84% | 22.47% | 21.31% | 18.02% | 19.04% | 7.35% | 20.35% | 20.82% | 20.91% | 20.37% | 20.19% | 18.55% | 21.81% | 13.16% |
| Operating Income | 53.41B | 39.22B | 59.62B | 56.54B | 138.68B | 99.92B | 75.60B | 51.21B | 42.78B | 28.34B | 66.40B | 70.46B | 95.75B | 113.12B | 86.41B | 91.81B | 17.75B | 105.26B | 95.70B | 86.81B | 83.06B | 75.86B | 72.69B | 58.97B | 37.13B |
| Operating Income Ratio | 7.20% | 5.27% | 7.88% | 8.75% | 19.94% | 15.54% | 12.60% | 9.50% | 7.81% | 5.17% | 11.08% | 12.28% | 14.78% | 14.71% | 10.76% | 11.74% | 2.42% | 15.61% | 15.92% | 16.28% | 16.61% | 16.26% | 16.84% | 16.30% | 12.28% |
| Total Other Income/Expenses | 8.42B | 4.97B | 708.00M | 1.04B | 2.56B | 3.30B | -409.00M | -1.40B | -1.46B | -2.46B | -4.10B | 966.00M | -1.10B | -10.55B | -12.13B | -21.32B | -96.00M | 5.07B | 378.00M | 845.00M | -539.00M | -6.04B | -9.93B | -16.13B | -11.60B |
| Income Before Tax | 61.82B | 45.01B | 54.46B | 52.55B | 128.06B | 89.45B | 76.80B | 57.67B | 50.47B | 25.88B | 62.30B | 71.43B | 94.65B | 102.57B | 74.28B | 70.48B | 17.65B | 110.33B | 96.08B | 87.65B | 82.52B | 69.83B | 62.75B | 42.84B | 25.54B |
| Income Before Tax Ratio | 8.33% | 6.05% | 7.20% | 8.14% | 18.41% | 13.92% | 12.80% | 10.70% | 9.21% | 4.72% | 10.39% | 12.45% | 14.61% | 13.34% | 9.25% | 9.02% | 2.40% | 16.37% | 15.98% | 16.44% | 16.50% | 14.97% | 14.54% | 11.84% | 8.44% |
| Income Tax Expense | 18.04B | -11.82B | 8.74B | 10.07B | 5.60B | 22.97B | 22.38B | 15.42B | -4.57B | -17.58B | 23.80B | 22.88B | 35.71B | 34.79B | 33.42B | 22.14B | 37.19B | 39.20B | 32.23B | 31.80B | 32.93B | 28.61B | -26.10B | 19.63B | 14.20B |
| Net Income | 42.41B | 55.43B | 47.95B | 41.94B | 121.77B | 63.39B | 51.85B | 39.36B | 54.93B | 43.25B | 38.25B | 48.28B | 58.51B | 67.39B | 40.34B | 47.68B | -17.01B | 70.61B | 63.41B | 55.51B | 50.15B | 41.03B | 36.51B | 23.09B | 11.28B |
| Net Income Ratio | 5.72% | 7.45% | 6.34% | 6.49% | 17.50% | 9.86% | 8.64% | 7.30% | 10.03% | 7.89% | 6.38% | 8.42% | 9.03% | 8.76% | 5.02% | 6.10% | -2.32% | 10.47% | 10.55% | 10.41% | 10.03% | 8.80% | 8.46% | 6.38% | 3.73% |
| EPS | 147.86 | 193.31 | 167.27 | 146.95 | 425.01 | 221.34 | 181.18 | 137.62 | 192.23 | 606.28 | 536.52 | 677.52 | 821.32 | 946.08 | 566.32 | 669.40 | -239.20 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| EPS Diluted | 147.86 | 193.30 | 167.25 | 146.90 | 424.80 | 221.12 | 180.97 | 137.41 | 191.76 | 605.48 | 536.04 | 677.24 | 821.24 | 946.04 | 566.24 | 669.20 | -239.20 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| Weighted Avg Shares Out | 286.80M | 286.76M | 286.69M | 286.62M | 286.51M | 286.37M | 286.16M | 285.98M | 285.76M | 71.44M | 71.34M | 71.25M | 71.24M | 71.23M | 71.23M | 71.23M | 71.12M | 71.23M | 71.47M | 71.45M | 71.94M | 74.14M | 72.93M | 74.11M | 74.11M |
| Weighted Avg Shares Out (Dil) | 286.80M | 286.76M | 286.73M | 286.71M | 286.65M | 286.66M | 286.48M | 286.42M | 286.47M | 71.62M | 71.44M | 71.25M | 71.24M | 71.24M | 71.24M | 71.25M | 71.12M | 71.23M | 71.47M | 71.45M | 71.94M | 74.14M | 72.93M | 74.11M | 74.11M |
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today a positive opinion has been received...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been...
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.
Eisai: Still Relatively Modest Market-Implied Expectations For Leqembi
Leqembi has just started its commercial journey, and in order to achieve an appropriate or even discounted multiple, relatively modest penetration of the drug in the US would be needed. Lenvima is also continuing with solid growth, seeming to be...
Eisai Co., Ltd. (ESALF) Q2 2025 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q2 2025 Earnings Conference Call November 8, 2024 1:00 AM ET Company Participants Haruo Naito - Representative Corporate Officer and CEO Akiko Nakahama - VP-Chief Portfolio Officer Japan / Asia Filing and Registration Katsuya Haruna -...
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
STOCKHOLM , Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from April 2024 through March 2025. Eisai now expects Leqembi...
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM , Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM , Oct. 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-soluble...
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive for wide use on Thursday.
Source: https://incomestatements.info
Category: Stock Reports